A Phase II trial examining the effects of combined inhibition of VEGFRs, PDGFRs, and c-KIT looked at simultaneous administration of Bevacizumab (detailed below) and Tandutinib in patients with recurrent GBM [276]. The gene discussed is KIT; the disease is glioblastoma.